|
Oct 1
|
PureTech to Present at CHEST 2024 Annual Meeting
|
|
Sep 30
|
FDA approves PureTech’s KarXT to treat schizophrenia in adults
|
|
Aug 28
|
PureTech Health plc – Half-Year Report
|
|
Jul 23
|
PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
|
|
Jun 13
|
PureTech Health: Results of Annual General Meeting
|
|
Apr 2
|
PureTech Health (PRTC) is on the Move, Here's Why the Trend Could be Sustainable
|
|
Jan 3
|
PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 22
|
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
|
|
Dec 20
|
PureTech Year End Update and Outlook for 2024
|
|
Dec 7
|
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
|
|
Nov 29
|
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
|
|
Nov 17
|
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
|
|
Apr 25
|
PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
|